Eli Lilly and Company $LLY Stock: Asset One Wealth Management LLC Increases Position

Asset One Wealth Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 10.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,769 shares of the company’s stock after purchasing an additional 620 shares during the quarter. Asset One Wealth Management LLC’s holdings in Eli Lilly and Company were worth $7,832,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Waldron Private Wealth LLC boosted its stake in shares of Eli Lilly and Company by 0.8% during the 3rd quarter. Waldron Private Wealth LLC now owns 8,312 shares of the company’s stock worth $9,618,000 after acquiring an additional 69 shares in the last quarter. Calamos Advisors LLC increased its holdings in Eli Lilly and Company by 2.2% in the 3rd quarter. Calamos Advisors LLC now owns 289,232 shares of the company’s stock worth $334,665,000 after acquiring an additional 6,231 shares during the last quarter. Financial Council LLC grew its position in Eli Lilly and Company by 0.6% during the 3rd quarter. Financial Council LLC now owns 1,255 shares of the company’s stock valued at $1,452,000 after purchasing an additional 8 shares during the last quarter. Burke & Herbert Bank & Trust Co. increased its position in shares of Eli Lilly and Company by 0.5% during the third quarter. Burke & Herbert Bank & Trust Co. now owns 5,255 shares of the company’s stock worth $6,080,000 after acquiring an additional 24 shares during the period. Finally, Alta Advisers Ltd increased its position in shares of Eli Lilly and Company by 85.0% during the 3rd quarter. Alta Advisers Ltd now owns 5,697 shares of the company’s stock worth $6,592,000 after purchasing an additional 2,618 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.5%

LLY opened at $1,372.15 on Friday. The stock has a market capitalization of $1.29 trillion, a P/E ratio of 44.54, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00. The business’s 50-day simple moving average is $1,215.24 and its 200-day simple moving average is $1,101.16.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. During the same period in the prior year, the business posted $7.02 earnings per share. Analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $17,020,770 over the last three months. Company insiders own 0.14% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Analyst Ratings Changes

Several equities research analysts have recently commented on LLY shares. The Goldman Sachs Group restated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Sanford C. Bernstein reissued an “outperform” rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a research note on Monday, October 26th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Finally, Royal Bank Of Canada lifted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,404.14.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.